616452
RepSox
≥95% (HPLC), solid, TGF-β RI kinase inhibitor, Calbiochem
别名:
TGF-β RI激酶抑制剂II, ALK5抑制剂II，转化生长因子-βI型受体激酶抑制剂II，2-（3-（6-甲基吡啶-2-基）-1H-吡唑-4-基）-1,5-萘啶
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H13N5
化学文摘社编号:
分子量:
287.32
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
产品名称
TGF-β RI激酶抑制剂II, TGF-β RI Kinase Inhibitor II, CAS 446859-33-2, is a cell-permeable, potent, reversible, ATP-competitive inhibitor of TGF-β R1 kinase (IC50 = 23 nM and 4 nM for ALK5 binding & auto-phosphorylation).
SMILES string
[nH]1ncc(c1c4nc(ccc4)C)c2nc3c(nccc3)cc2
InChI
1S/C17H13N5/c1-11-4-2-5-16(20-11)17-12(10-19-22-17)13-7-8-14-15(21-13)6-3-9-18-14/h2-10H,1H3,(H,19,22)
InChI key
LBPKYPYHDKKRFS-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
solid
potency
23 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
yellow
solubility
DMSO: 5 mg/mL
methanol: 5 mg/mL
shipped in
ambient
Quality Level
storage temp.
2-8°C
Biochem/physiol Actions
主靶
ALKS结合
ALKS结合
产物与ATP竞争。
次级靶标
ALK 5自身磷酸化(IC₅₀= 4 nM)
ALK 5自身磷酸化(IC₅₀= 4 nM)
细胞可渗透性：是
Disclaimer
毒性：标准处理（A）
General description
一种细胞渗透性萘啶基吡唑化合物，可作为TGF-βⅠ型受体的有效、选择性、可逆和ATP竞争性抑制剂（ALK5；ALK5结合、ALK5自动磷酸化和HepG2细胞中TGF-β细胞分析的IC50分别为23 nM、4 nM和18 nM）。对9种密切相关的激酶的影响最小，包括IC50 >16 µM的p38 MAPK。也可作为50 mM的DMSO溶液（目录号508158）提供。
Other Notes
Gellibert, F., et al. 2004.J. Med. Chem.47, 4494.
Ichida, J. K., et al. 2009.Cell Stem Cell 5, 491.
Ichida, J. K., et al. 2009.Cell Stem Cell 5, 491.
Packaging
用惰性气体包装
Preparation Note
复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多6个月。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Satoru Shinriki et al.
The Journal of pathology, 244(3), 367-379 (2017-12-14)
Oral squamous cell carcinoma (OSCC) has a very poor prognosis because of its highly invasive nature, and the 5-year survival rate has not changed appreciably for the past 30 years. Although cylindromatosis (CYLD), a deubiquitinating enzyme, is thought to be a
Ayumi Kanemaru et al.
Cancer cell international, 22(1), 358-358 (2022-11-16)
Tumor suppressor CYLD dysfunction by loss of its expression, triggers malignant transformation, especially drug resistance and tumor invasion/metastasis. Although loss of CYLD expression is significantly associated with poor prognosis in a large variety of tumors, no clinically-effective treatment for CYLD-negative
Ana Guerrero et al.
Nature aging, 2, 851-866 (2022-11-29)
Cellular senescence is a stable type of cell cycle arrest triggered by different stresses. As such, senescence drives age-related diseases and curbs cellular replicative potential. Here, we show that 3-deazaadenosine (3DA), an S-adenosyl homocysteinase (AHCY) inhibitor, alleviates replicative and oncogene-induced
Mikolaj M Kozlowski et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 40(13), 2618-2632 (2020-02-23)
Sensory hair cell losses underlie the vast majority of permanent hearing and balance deficits in humans, but many nonmammalian vertebrates can fully recover from hearing impairments and balance dysfunctions because supporting cells (SCs) in their ears retain lifelong regenerative capacities
Sayaka Imatsuji et al.
Oncology research, 32(1), 139-150 (2024-01-08)
Growing evidence suggests an association between epithelial-mesenchymal transition (EMT), a hallmark of tumor malignancy, and chemoresistance to a number of anti-cancer drugs. However, the mechanism of EMT induction in the process of acquiring anti-cancer drug resistance remains unclear. To address
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持